Lakatos v. Envision Healthcare

CourtDistrict Court, S.D. Florida
DecidedApril 28, 2025
Docket1:24-cv-21357
StatusUnknown

This text of Lakatos v. Envision Healthcare (Lakatos v. Envision Healthcare) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lakatos v. Envision Healthcare, (S.D. Fla. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

Case No. 24-cv-21357-BLOOM/Elfenbein

JASON M. LAKATOS,

Plaintiff,

v.

FLORIDA IPS,

Defendant. _________________________/

ORDER ON MOTION TO DISMISS THIS CAUSE is before the Court upon Defendant Florida IPS Medical Services’ (“IPS”) Motion to Dismiss Plaintiff’s Third Amended Complaint (“Motion”), ECF No. [63], filed on January 21, 2025. Plaintiff Jason M. Lakatos (“Dr. Lakatos”), filed a Response, ECF No. [65], to which IPS filed a Reply, ECF No. [72]. The Court has reviewed the record, the supporting and opposing submissions, the applicable law, and is otherwise fully advised. For the reasons that follow, the Motion is granted in part and denied in part. I. BACKGROUND

On April 11, 2024, Dr. Lakatos filed suit against Envision Healthcare (“Envision”) and HCA Healthcare. ECF No. [1]. Dr. Lakatos thereafter filed an Amended Complaint, ECF No. [10], and then a Second Amended Complaint, ECF No. [25], against Envision and IPS. On August 12, 2024, the Court entered its Order dismissing Envision with prejudice and Dr. Lakatos was “permanently enjoined from pursuing this action by Defendant’s petition for relief under Chapter 11 of Title II of the United States Code, 11 U.S.C. §§ 101-1532, in the United States District Court for the Southern District of Texas.” ECF No. [47]. On December 6, 2024, the Court granted IPS’s Motion to Dismiss without prejudice, ECF No. [55], and Dr. Lakatos was granted leave to file a Third Amended Complaint (“TAC”) by December 20, 2024. Id. Dr. Lakatos timely filed his TAC1 on December 19, 2024, ECF No. [56], and asserts five counts against IPS2: (1) Wrongful Termination/Breach of Contract; (2) Malicious

Interference with Contractual Rights Under State Law; (3) Breach of Contract and Breach of the Implied Covenant of the Duty of Good Faith and Fair Dealing; (4) Violation of Florida Whistleblower Act under Florida Statute 448.102; and (5) Defamation.3 The facts alleged in the TAC are largely identical to the facts alleged in the Second Amended Complaint. ECF Nos. [25], [56]. Because the Court provided an exhaustive account of the factual background in its December 6, 2024 Order, ECF No. [55], it addresses only those allegations necessary to decide the Motion. Dr. Lakatos alleges that he is an internal medicine physician who “worked the ‘front line’ of the COVID-19 pandemic. At a time when the world was more ignorant about the pandemic than it was knowledgeable, Dr. Lakatos dedicated himself to research in pursuit of the best way to treat

his COVID-19 patients.” ECF No. [56] at 1. In October 2018, Dr. Lakatos was recruited by “third- party employer” Envision to become “a full-time traveling hospitalist.” Id. ¶¶ 10-12. Dr. Lakatos alleges that he “signed an employment agreement and completed the extensive credentialing

1 Plaintiff captioned his operative complaint as his “Second Amended Complaint,” however, it is his Third Amended Complaint. See ECF Nos. [1], [10], [25], [56]. Although on April 16, 2024, Dr. Lakatos filed three separate documents entitled “Amended Complaint,” the multiple entries appear to be due to difficulties with docketing and do not present further amendments the Complaint. 2 The TAC alleges that Dr. Lakatos is bringing these counts against “Envision Healthcare and Florida IPS Medical Services.” ECF No. [56] at 1. In accordance with the Court’s August 12, 2024 Order, the Court dismissed the TAC with prejudice as to Envision. ECF No. [62]. Therefore, only IPS remains in the suit. 3 The TAC improperly referred to the defamation claim as “Count IV.” The Court will use the correct numbering and refer to it as Count V. packets for Envision.” Id. ¶ 13. He further alleges that he “was guaranteed and required to work 1800 hours per year per his employment agreement with Envision Healthcare/Envision Physician Services.” Id. ¶ 20. “During his employment with Envision . . . Dr. Lakatos was placed in various hospitals with physician deficiencies” including IPS facilities. Id. ¶ 22.

In the early months of the pandemic, “Dr. Lakatos applied his medical knowledge and research skills to identify medications that would aid in the fight against COVID and help his patients recover from an otherwise deadly disease.” Id. ¶ 33. As a result of that research, Dr. Lakatos began using hydroxychloroquine (“HCQ”) to treat COVID patients. Id. ¶ 37. Dr. Lakatos alleges his use of HCQ was successful and that he “strongly felt that he had indeed found a curative treatment regimen for COVID-19 and one without any significant side effects outside of simple effects (nausea, headache, diarrhea).” Id. ¶ 49. However, beginning in June 2020, IPS “required all COVID-19 patients to be treated with Remdesivir if they had confirmed positive COVID-19 and [their] oxygen saturations were less than 93%.” Id. ¶ 63. Dr. Lakatos alleges that “[t]he hospitals tried to force [him] to treat his COVID-19 patients with this experimental drug

Remdesivir instead of the safe and effective treatment course he had identified and successfully used for the last two-and-a half months.” Id. ¶ 70. Although Dr. Lakatos attempted to prescribe HCQ, “[i]n mid to late June of 2020, pharmacists at both Lawnwood Regional Medical Center and Palms West Medical facilities began denying Dr. Lakatos’s patients’ prescriptions for HCQ.” Id. ¶ 77. Despite being “banned from using that key medication as a form of treatment” Dr. Lakatos “refused to follow guidelines that recommended treatments that he had seen with proven harms and limited efficacy.” Id. ¶¶ 81, 86. Dr. Lakatos alleges that around January 2021, “Lawnwood pharmacists started flatly refusing to fill [his] prescriptions without confirmation from Lawnwood CMO, Dr. Bakerman.” Id. ¶ 99. In February 2021, Dr. Lakatos alleges, he “voiced his concerns

during a phone call with Dr. Bakerman regarding Lawnwood treatment practices and procedures as well as the alterations of his orders.” Id. ¶ 100. During the phone call, Dr. Lakatos told Dr. Bakerman that “he was receiving emails from [Dr. Bakerman] instructing him on how to properly commit the fraud and . . . was not going to lie on HCA’s behalf in his notes regarding these patients.” Id. He also stated that “what the pharmacists were doing is essentially practicing

medicine without a license.” Id. After this conversation, “Dr. Bakerman decided to report Dr. Lakatos to the regional director for Envision and threatened to have him ‘blackballed’ and banned from [all IPS] facilities.” Id. ¶ 102. Dr. Lakatos alleges that “[t]hese threats were a direct result of both Dr. Lakatos’s attempts to prescribe HCQ, as well as his whistleblowing about many of the illegal medical practices undertaken” at IPS’s Lawnwood Regional Medical Center. Id. ¶ 104. Dr. Lakatos “felt admonished and very uncomfortable with continuing to work at this facility, so he requested a transfer[.]” Id. ¶ 105. Following his transfer to a new hospital, Dr. Lakatos “ordered his typical COVID-19 orders that he had been successfully using at Lawnwood over the last several months, including Ivermectin.” Id. ¶ 107. However, “Dr. Lakatos received a phone call from the pharmacist stating he wasn’t allowed to use this medication (Ivermectin) for

COVID-19.” Id. ¶ 108. The pharmacist stated that HCQ was also “not allowed for treatment of COVID-19.” Id. Although Dr. Lakatos “tried to reason with the pharmacist and direct him to studies showing efficacy . . . the pharmacist said it didn’t matter as this was . . . IPS corporate policy.” Id. Dr. Lakatos subsequently “had a 20-minute discussion about Ivermectin” with the Chief Medical Officer, Dr. Jorge Gonzalez, and one of the pharmacists. Id. ¶ 109. During this conversation, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burger King Corp. v. Weaver
169 F.3d 1310 (Eleventh Circuit, 1999)
Wagner v. Daewoo Heavy Industries America Corp.
314 F.3d 541 (Eleventh Circuit, 2002)
Centurion Air Cargo, Inc. v. United Parcel Service Co.
420 F.3d 1146 (Eleventh Circuit, 2005)
Ronald Thaeter v. Palm Beach Co. Sheriff's Office
449 F.3d 1342 (Eleventh Circuit, 2006)
Robert Garfield v. NDCHealth Corporation
466 F.3d 1255 (Eleventh Circuit, 2006)
US EX REL. SANCHEZ v. Lymphatx, Inc.
596 F.3d 1300 (Eleventh Circuit, 2010)
Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Vernon E. Hargray v. City of Hallandale
57 F.3d 1560 (Eleventh Circuit, 1995)
MDS (Canada) Inc. v. Rad Source Technologies, Inc.
720 F.3d 833 (Eleventh Circuit, 2013)
Mariscotti v. Merco Group at Akoya, Inc.
917 So. 2d 890 (District Court of Appeal of Florida, 2005)
McKinney-Green, Inc. v. Davis
606 So. 2d 393 (District Court of Appeal of Florida, 1992)
Covelli Family, LP v. ABG5, LLC
977 So. 2d 749 (District Court of Appeal of Florida, 2008)
Quaker Oats Co. v. Jewell
818 So. 2d 574 (District Court of Appeal of Florida, 2002)
Snow v. Ruden, McClosky, Smith, Schuster
896 So. 2d 787 (District Court of Appeal of Florida, 2005)
Jews for Jesus, Inc. v. Rapp
997 So. 2d 1098 (Supreme Court of Florida, 2008)
Woodham v. Blue Cross and Blue Shield of Fla., Inc.
829 So. 2d 891 (Supreme Court of Florida, 2002)
Farah v. Canada
740 So. 2d 560 (District Court of Appeal of Florida, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Lakatos v. Envision Healthcare, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lakatos-v-envision-healthcare-flsd-2025.